STOCKHOLDERS' DEFICIT (Details) - USD ($)																	3 Months Ended	12 Months Ended
STOCKHOLDERS' DEFICIT (Details) - USD ($)	Oct. 01, 2022	Apr. 05, 2022	Mar. 31, 2022	Mar. 11, 2022	Feb. 26, 2022	Oct. 01, 2021	Sep. 10, 2021	Apr. 01, 2021	Mar. 23, 2021	Feb. 10, 2021	Oct. 01, 2020	May 07, 2018	Aug. 07, 2017	Apr. 21, 2017	Sep. 16, 2016	Oct. 07, 2015	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Feb. 26, 2021	Dec. 31, 2020	Feb. 05, 2020	Jun. 15, 2019	Nov. 02, 2015	Aug. 04, 2014	Apr. 01, 2013
STOCKHOLDERS' DEFICIT (Details) [Line Items]
Adjustments to Additional Paid in Capital, Other																		$ 384,174	$ 0
Convertible Debt Discount Increase Decrease																		241,589
Retained Earnings Increase Decrease																		142,585
Stock Issued During Period, Value, Other																		48,817	231,742
Gain (Loss) on Extinguishment of Debt	$ 450	$ 722				$ 274		$ (1,734)		$ 100,000	$ (984)						$ 447,494	(447,494)	0
Debt Conversion, Original Debt, Amount			$ 27,000	$ 25,000				9,145								$ 100,000		$ 25,000	$ 375,586
Stock Issued During Period, Shares, Issued for Services (in Shares)																		45,000,000	4,000,000
Stock Issued During Period, Value, Issued for Services																		$ 297,000	$ 128,000
Debt Conversion, Converted Instrument, Amount	$ 9,645	$ 9,866			$ 25,000	$ 8,921		$ 10,879
Debt Conversion, Converted Instrument, Shares Issued (in Shares)	1,377,891	1,121,154	6,750,000	3,125,000	3,125,000	743,341		187,575	7,518,797		2,035,820					34,522			28,891,144
Common Stock Registered, Shares (in Shares)							250,000,000
Proceeds from Issuance of Common Stock																		$ 85,000	$ 275,000
Stock Issued During Period, Shares, New Issues (in Shares)																	53,400,000	13,958,334	27,500,000
Debt Instrument, Face Amount					$ 25,000																	$ 35,000	$ 500,000
Class of Warrant or Rights, Granted (in Shares)																	12,500,000	12,500,000	0
Class of Warrant or Rights, Weighted-Average Exercise Price of Warrants or Rights, Granted (in Dollars per share)																	$ 0.008	$ 0.008
Adjustments to Additional Paid in Capital, Warrant Issued																	$ 491,607
Extinguishment of Debt, Amount																	294,000
Debt Instrument, Unamortized Discount			$ 44,113														$ 44,113
Stock Issued During Period, Value, New Issues																		$ 85,000	$ 275,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value																		5,500	36,686		$ 296,636
Share-Based Payment Arrangement, Noncash Expense																		$ 384,380	$ 556,556
Debt Instrument, Maturity Date, Description																	extended for two years
Bioheart 2013 Omnibus Equity Compensation Plan [Member]
STOCKHOLDERS' DEFICIT (Details) [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in Shares)																								500,000,000,000,000	100,000,000	50,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in Shares)												100,000,000	30,000,000	25,000,000	25,000,000
Maximum [Member]
STOCKHOLDERS' DEFICIT (Details) [Line Items]
Proceeds from Issuance of Common Stock							$ 2,500,000
Interest [Member]
STOCKHOLDERS' DEFICIT (Details) [Line Items]
Stock Issued During Period, Shares, Other (in Shares)																		2,499,045	930,916
Stock Issued During Period, Value, Other																		$ 19,511	$ 19,800
Gain (Loss) on Extinguishment of Debt																		1,171	1,459
Debt Conversion, Original Debt, Amount																		$ 18,340	18,340
Debt Conversion, Converted Instrument, Amount																			586
Principal [Member]
STOCKHOLDERS' DEFICIT (Details) [Line Items]
Debt Conversion, Converted Instrument, Amount																			$ 375,000
Convertible Debt [Member]
STOCKHOLDERS' DEFICIT (Details) [Line Items]
Debt Instrument, Face Amount			$ 214,000														$ 214,000			$ 200,000
Debt Instrument, Convertible, Conversion Price (in Dollars per share)			$ 0.0266														$ 0.0266
Debt Instrument, Convertible, Conversion Price, Decrease (in Dollars per share)																	$ 0.008
Convertible Note February 26, 2022 [Member]
STOCKHOLDERS' DEFICIT (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares)					6,750,000
Debt Instrument, Face Amount					$ 27,000
Debt Instrument, Unamortized Discount					18,563
Proceeds from Issuance of Debt					27,000
Stock Issued During Period, Value, New Issues					$ 18,563
Debt Instrument, Term					24 months
Accounts Payable [Member]
STOCKHOLDERS' DEFICIT (Details) [Line Items]
Stock Issued During Period, Shares, Other (in Shares)																		6,145,193	6,642,197
Stock Issued During Period, Value, Other																		$ 48,817	$ 231,742
Gain (Loss) on Extinguishment of Debt																			151,742
Debt Conversion, Original Debt, Amount																		50,000
Common Stock Issued in Settlement of Accounts Payable, Accrued Expenses and Accrued Interest [Member]
STOCKHOLDERS' DEFICIT (Details) [Line Items]
Gain (Loss) on Extinguishment of Debt																		(1,183)
Share-Based Payment Arrangement, Option [Member]
STOCKHOLDERS' DEFICIT (Details) [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value																		$ 5,500
Share Price (in Dollars per share)																		$ 0.0048
Share-Based Payment Arrangement, Noncash Expense																		$ 134,974	$ 428,556
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount																		$ 22,315
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition																		5 months 19 days
Warrant [Member]
STOCKHOLDERS' DEFICIT (Details) [Line Items]
Share Price (in Dollars per share)																		$ 0.0048

U.S. Stem Cell, Inc. 10-K